1.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;3841(11):989-1002.
2.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. (40 countries) reflecting estimates of real-world activity
3.
Based on internal analysis by Novo Nordisk using data from the following source: IQVIA MIDAS® monthly volume sales data, ATC3 A10S and A8A, for the time period 01.2018 to 07.2024 (40 countries) reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved
4.
Resumen de las características del producto. Wegovy®. Disponible en: https://www.ema.europa.eu/es/documents/product-information/wegovy-epar-product-information_es.pdf. Ultima revision 12 de Junio 2024.